Fentanyl controlled-release - Onxeo

Drug Profile

Fentanyl controlled-release - Onxeo

Alternative Names: BA-041; Fentanyl Lauriad

Latest Information Update: 03 Sep 2014

Price : $50

At a glance

  • Originator BioAlliance Pharma
  • Developer Onxeo SA
  • Class General anaesthetics; Opioid analgesics; Piperidines; Small molecules
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Cancer pain

Highest Development Phases

  • Discontinued Cancer pain

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 03 Sep 2014 Discontinued - Phase-I/II for Cancer pain (In volunteers) in France (Buccal)
  • 01 Aug 2014 TopoTarget has merged with BioAlliance Pharma to form Onxeo SA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top